Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
Rodrigo R R DuarteDennis C CopertinoLuis P IñiguezJez L MarstonYaron BramYuling HanRobert E SchwartzShuibing ChenDouglas F NixonTimothy R PowellPublished in: Molecular medicine (Cambridge, Mass.) (2021)
Small clinical studies reported that general statin use, and specifically, atorvastatin use, are associated with protective effects against COVID-19. Our study corroborrates these findings and supports the investigation of atorvastatin in larger clinical studies. Ultimately, our framework demonstrates one promising way to fast-track the identification of compounds for COVID-19, which could similarly be applied when tackling future pandemics.